Contrasting of Avid Bioservices Inc. (CDMOP) and InflaRx N.V. (NASDAQ:IFRX)

Avid Bioservices Inc. (NASDAQ:CDMOP) and InflaRx N.V. (NASDAQ:IFRX) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avid Bioservices Inc. 43.49M 4.75 16.11M -0.31 0.00
InflaRx N.V. N/A 0.00 N/A -1.42 0.00

Demonstrates Avid Bioservices Inc. and InflaRx N.V. earnings per share, gross revenue and valuation.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Avid Bioservices Inc. -37.04% 0% 0%
InflaRx N.V. 0.00% -22.7% -21.9%

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Avid Bioservices Inc. and InflaRx N.V.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Avid Bioservices Inc. 0 0 0 0.00
InflaRx N.V. 0 0 1 3.00

Competitively the consensus price target of InflaRx N.V. is $58, which is potential 40.13% upside.

Institutional and Insider Ownership

Avid Bioservices Inc. and InflaRx N.V. has shares owned by institutional investors as follows: 0.72% and 58.4%. Avid Bioservices Inc.’s share owned by insiders are 7.06%.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Avid Bioservices Inc. 0.85% 1.09% 8.25% 1.61% 6.87% 3.88%
InflaRx N.V. 16.4% 16.44% 25.22% 14.31% 39.39% 4.98%

For the past year Avid Bioservices Inc.’s stock price has smaller growth than InflaRx N.V.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *